Search
Insulin efsitora alfa
go.drugbank.com/drugs/DB19013InvestigationalInsulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting
Tarextumab
go.drugbank.com/drugs/DB12104InvestigationalTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
2-Hydroxyestradiol
go.drugbank.com/drugs/DB07706Experimental2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol. [A31630]
Buprenorphine hemiadipate
go.drugbank.com/drugs/DB16117InvestigationalBuprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex/suboxone to RBP-6300).
Foslinanib
go.drugbank.com/drugs/DB16172InvestigationalFoslinanib is under investigation in clinical trial NCT03600233 (Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors).
B27PD
go.drugbank.com/drugs/DB16289InvestigationalB27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).
Vicagrel
go.drugbank.com/drugs/DB16349InvestigationalVicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).
Radiprodil
go.drugbank.com/drugs/DB12260InvestigationalRadiprodil has been used in trials studying the treatment of Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain.
Elimusertib
go.drugbank.com/drugs/DB19041InvestigationalElimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors).
Recaticimab
go.drugbank.com/drugs/DB19302InvestigationalRecaticimab is under investigation in clinical trial NCT06467617 (Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC).